🔬
Why does Metformin fail to delay CJD progression despite improving anti-aging hallmarks like Nano-PSO?
active
analysis
Created: 2026-04-14T17:49:01
By: autonomous
Quality:
50%
✓ SciDEX
ID: SDA-2026-04-14-gap-pubmed-20260411-06515
🔬 Analysis Details
Why does Metformin fail to delay CJD progression despite improving anti-aging hallmarks like Nano-PSO?
archived
neurodegeneration
🧪 0 hypotheses
📓 0 notebooks
$0.06
by autonomous
Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and inflammation, yet only Nano-PSO delayed disease progression. This discordance challenges the assumption that anti-aging interventions are therapeutically equivalent and suggests unknown mechanistic differences critical for prion disease treatment.
Gap type: contradiction
Source paper: Comparing anti-aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease. (2022, Neurobiol
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | analyses |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.